title: Sirolimus-based immunosuppression in kidney transplantation for type 2 diabetic nephropathy.
abstract: BACKGROUND
  Kidney transplantation is the best replacement therapy of type 2 diabetic patients and recently similar graft and patient survival between diabetic and nondiabetic recipients has been reported. However, standard immunosuppressive protocols are lacking. We present our experience with sirolimus-based immunosuppression in a population of 24 type 2 diabetic patients who underwent a kidney transplantation.
  
  
  METHODS
  From January 2001 to December 2006, 396 kidney transplantations were performed. Twenty-four patients had type 2 diabetes mellitus as a cause of end-stage renal disease. They were randomized in two groups: thirteen patients (group A) received an immunosuppressive treatment with sirolimus, low-dose tacrolimus and steroids, while 11 patients (group B) received sirolimus, mycophenolate mofetil and steroids.
  
  
  RESULTS
  Clinical characteristics were similar between the two groups. A slightly better kidney functionality was observed in group B patients. There were neither acute rejection episodes nor severe infectious complications in both groups. One patient in each group underwent a foot amputation. Graft and patient survival was 100% for both groups at a median follow-up of 29 months.
  
  
  CONCLUSIONS
  Sirolimus-based immunosuppression is safe and efficacious in type 2 diabetic patients who underwent a kidney transplantation, allowing a better glucose metabolism control.
authors.affiliation: Department of Surgery, Transplantation and Advanced Technologies - Vascular Surgery and Organ Transplant Unit, University Hospital of Catania, Catania, Italy. veroux@unict.it
authors.forename: Massimiliano
authors.initials: M
authors.lastname: Veroux
authors.forename: D
authors.initials: D
authors.lastname: Corona
authors.forename: G
authors.initials: G
authors.lastname: Giuffrida
authors.forename: M
authors.initials: M
authors.lastname: Gagliano
authors.forename: D
authors.initials: D
authors.lastname: Vizcarra
authors.forename: T
authors.initials: T
authors.lastname: Tallarita
authors.forename: D
authors.initials: D
authors.lastname: Zerbo
authors.forename: A
authors.initials: A
authors.lastname: Giaquinta
authors.forename: M
authors.initials: M
authors.lastname: Sorbello
authors.forename: M
authors.initials: M
authors.lastname: Macarone
authors.forename: P
authors.initials: P
authors.lastname: Veroux
mesh_terms: D003924:Diabetes Mellitus, Type 2 / Q000150:complications*; D003928:Diabetic Nephropathies / Q000209:etiology* / Q000601:surgery*; D006801:Humans; D007165:Immunosuppression Therapy; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016030:Kidney Transplantation; D008875:Middle Aged; D012189:Retrospective Studies; D020123:Sirolimus / Q000627:therapeutic use*
chemical_list: D007166:Immunosuppressive Agents; D020123:Sirolimus